Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
$8.50
$7.72
$6.60
$14.60
$2.01B1.447,996 shs14 shs
Repligen Co. stock logo
RGEN
Repligen
$118.15
-1.9%
$130.28
$102.97
$182.52
$6.64B1.21740,875 shs615,767 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$39.77
+2.5%
$37.55
$29.17
$62.40
$7.23B1.111.49 million shs1.40 million shs
Bio-Techne Co. stock logo
TECH
Bio-Techne
$46.78
-1.1%
$52.10
$46.01
$83.62
$7.33B1.461.30 million shs1.47 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
0.00%+3.16%+10.17%+5.26%-0.93%
Repligen Co. stock logo
RGEN
Repligen
-1.91%-6.60%-16.52%-25.69%-28.45%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+2.50%+0.58%+6.08%-3.80%0.00%
Bio-Techne Co. stock logo
TECH
Bio-Techne
-1.14%-4.82%-6.77%-27.94%-43.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
N/AN/AN/AN/AN/AN/AN/AN/A
Repligen Co. stock logo
RGEN
Repligen
4.8214 of 5 stars
4.31.00.04.54.13.31.9
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4.3481 of 5 stars
4.51.00.04.73.42.50.0
Bio-Techne Co. stock logo
TECH
Bio-Techne
4.8451 of 5 stars
4.23.01.74.23.11.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
0.00
N/AN/AN/A
Repligen Co. stock logo
RGEN
Repligen
2.64
Moderate Buy$173.2546.64% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
3.00
Buy$67.0868.68% Upside
Bio-Techne Co. stock logo
TECH
Bio-Techne
2.40
Hold$73.4457.00% Upside

Current Analyst Ratings Breakdown

Latest BVNRY, TECH, RVMD, and RGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$73.00 ➝ $72.00
5/9/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$95.00 ➝ $70.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$67.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$87.00 ➝ $80.00
5/8/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$57.00 ➝ $57.00
5/8/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$72.00 ➝ $63.00
5/8/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$75.00 ➝ $60.00
5/8/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$95.00 ➝ $75.00
5/5/2025
Repligen Co. stock logo
RGEN
Repligen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$180.00 ➝ $180.00
4/30/2025
Repligen Co. stock logo
RGEN
Repligen
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$202.00 ➝ $189.00
(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
$1.02B1.96$2.04 per share4.17$6.41 per share1.33
Repligen Co. stock logo
RGEN
Repligen
$650.43M10.21$2.20 per share53.61$35.19 per share3.36
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$742K9,983.66N/AN/A$11.09 per share3.59
Bio-Techne Co. stock logo
TECH
Bio-Techne
$1.21B6.07$1.65 per share28.30$13.15 per share3.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
$214.20M$0.8012.328.10N/A18.33%10.65%7.90%N/A
Repligen Co. stock logo
RGEN
Repligen
$35.60M-$0.45N/A50.064.54-4.64%4.21%2.94%7/29/2025 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$436.37M-$4.00N/AN/AN/AN/A-33.67%-30.08%8/6/2025 (Estimated)
Bio-Techne Co. stock logo
TECH
Bio-Techne
$168.10M$0.8247.2523.752.8813.22%12.73%9.75%8/6/2025 (Estimated)

Latest BVNRY, TECH, RVMD, and RGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
N/A$0.13N/A$0.13N/A$189.89 million
5/7/2025Q1 2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.12-$1.13-$0.01-$1.13N/AN/A
5/7/2025Q3 2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
$0.51$0.56+$0.05$0.14$317.92 million$316.18 million
4/29/2025Q1 2025
Repligen Co. stock logo
RGEN
Repligen
$0.35$0.39+$0.04$0.10$163.65 million$169.17 million
3/5/2025Q4 2024
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
$0.40$0.47+$0.07$0.47$264.06 million$299.48 million
2/26/2025Q4 2024
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.01-$1.12-$0.11-$1.12$0.35 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
N/AN/AN/AN/AN/A
Repligen Co. stock logo
RGEN
Repligen
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
$0.320.68%N/A39.02%N/A

Latest BVNRY, TECH, RVMD, and RGEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/19/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
quarterly$0.080.67%5/19/20255/19/20255/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
N/A
1.69
0.98
Repligen Co. stock logo
RGEN
Repligen
0.26
10.44
8.76
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/A
14.24
14.24
Bio-Techne Co. stock logo
TECH
Bio-Techne
0.14
3.94
2.77

Institutional Ownership

CompanyInstitutional Ownership
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
N/A
Repligen Co. stock logo
RGEN
Repligen
97.64%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%
Bio-Techne Co. stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
N/A
Repligen Co. stock logo
RGEN
Repligen
1.20%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
8.20%
Bio-Techne Co. stock logo
TECH
Bio-Techne
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bavarian Nordic A/S stock logo
BVNRY
Bavarian Nordic A/S
1,379236.57 millionN/ANot Optionable
Repligen Co. stock logo
RGEN
Repligen
2,02056.18 million55.36 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250186.27 million154.76 millionOptionable
Bio-Techne Co. stock logo
TECH
Bio-Techne
3,000156.77 million151.92 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bavarian Nordic A/S stock logo

Bavarian Nordic A/S OTCMKTS:BVNRY

$8.50 0.00 (0.00%)
As of 05/23/2025

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Repligen stock logo

Repligen NASDAQ:RGEN

$118.15 -2.30 (-1.91%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$119.02 +0.87 (+0.74%)
As of 05/23/2025 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$39.77 +0.97 (+2.50%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$39.98 +0.20 (+0.52%)
As of 05/23/2025 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$46.78 -0.54 (-1.14%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$46.94 +0.16 (+0.34%)
As of 05/23/2025 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.